EGRX
Income statement / Annual
Last year (2022), Eagle Pharmaceuticals, Inc.'s total revenue was $316.61 M,
an increase of 84.56% from the previous year.
In 2022, Eagle Pharmaceuticals, Inc.'s net income was $35.64 M.
See Eagle Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
09/30/2014 |
09/30/2013 |
| Operating Revenue |
$316.61 M
|
$171.55 M
|
$187.80 M
|
$195.89 M
|
$213.31 M
|
$236.71 M
|
$189.48 M
|
$66.23 M
|
$19.10 M
|
$13.68 M
|
| Cost of Revenue |
$94.94 M |
$42.18 M |
$45.47 M |
$60.90 M |
$61.92 M |
$57.19 M |
$55.31 M |
$15.65 M |
$11.71 M |
$7.38 M |
| Gross Profit |
$221.67 M |
$129.37 M |
$142.34 M |
$135.00 M |
$151.40 M |
$179.52 M |
$134.18 M |
$50.58 M |
$7.39 M |
$6.30 M |
| Gross Profit Ratio |
0.7 |
0.75 |
0.76 |
0.69 |
0.71 |
0.76 |
0.71 |
0.76 |
0.39 |
0.46 |
| Research and Development
Expenses |
$34.09 M
|
$51.28 M
|
$30.79 M
|
$36.81 M
|
$44.42 M
|
$32.61 M
|
$30.26 M
|
$27.86 M
|
$16.82 M
|
$9.80 M
|
| General & Administrative
Expenses |
$98.13 M
|
$66.82 M
|
$75.90 M
|
$73.97 M
|
$57.21 M
|
$73.07 M
|
$37.53 M
|
$15.41 M
|
$5.02 M
|
$0.00
|
| Selling & Marketing
Expenses |
$8.50 M
|
$8.50 M
|
$2.70 M
|
$2.40 M
|
$3.30 M
|
-$1.65 M
|
$14.78 M
|
$4.75 M
|
$4.30 M
|
$0.00
|
| Selling, General &
Administrative Expenses |
$106.63 M
|
$75.32 M
|
$78.60 M
|
$76.37 M
|
$60.51 M
|
$71.42 M
|
$52.31 M
|
$20.17 M
|
$9.33 M
|
$4.96 M
|
| Other Expenses |
$0.00 |
-$6.24 M |
-$8.26 M |
$700,000.00 |
$52.23 M |
$35.22 M |
$32.57 M |
$0.00 |
$35,000.00 |
$3,202.00 |
| Operating Expenses |
$140.71 M |
$126.60 M |
$109.38 M |
$113.18 M |
$104.93 M |
$104.02 M |
$82.58 M |
$48.02 M |
$26.14 M |
$14.75 M |
| Cost And Expenses |
$235.65 M |
$168.78 M |
$154.85 M |
$174.08 M |
$166.84 M |
$161.21 M |
$137.88 M |
$63.67 M |
$37.86 M |
$22.13 M |
| Interest Income |
$271,000.00 |
$560,000.00 |
$562,000.00 |
$2.17 M |
$158,000.00 |
$91,000.00 |
$84,000.00 |
$25,000.00 |
$31,000.00 |
$3,212.00 |
| Interest Expense |
$4.05 M |
$1.64 M |
$2.58 M |
$2.69 M |
$2.74 M |
$1.14 M |
$8,000.00 |
$11,000.00 |
$8,000.00 |
$1.40 M |
| Depreciation &
Amortization |
$12.02 M
|
$4.81 M
|
$4.77 M
|
$4.65 M
|
$3.67 M
|
$3.75 M
|
$1.59 M
|
$112,000.00
|
$104,000.00
|
$134,994.00
|
| EBITDA |
$77.50 M
|
$2.77 M
|
$30.02 M
|
$28.18 M
|
$40.44 M
|
$77.83 M
|
$55.02 M
|
$2.70 M
|
-$18.76 M
|
-$8.41 M
|
| EBITDA Ratio |
0.24 |
0 |
0.16 |
0.15 |
0.24 |
0.34 |
0.27 |
0.04 |
-0.98 |
-0.61 |
| Operating Income Ratio
|
0.26
|
-0.02
|
0.13
|
0.11
|
0.17
|
0.31
|
0.28
|
0.04
|
-0.98
|
-0.62
|
| Total Other
Income/Expenses Net |
-$19.53 M
|
-$7.32 M
|
-$10.28 M
|
$183,000.00
|
-$2.58 M
|
-$1.05 M
|
$76,000.00
|
$14,000.00
|
-$515,000.00
|
$1.51 M
|
| Income Before Tax |
$61.43 M |
-$4.55 M |
$22.68 M |
$22.00 M |
$34.04 M |
$72.95 M |
$53.43 M |
$2.57 M |
-$19.27 M |
-$6.95 M |
| Income Before Tax Ratio
|
0.19
|
-0.03
|
0.12
|
0.11
|
0.16
|
0.31
|
0.28
|
0.04
|
-1.01
|
-0.51
|
| Income Tax Expense |
$25.79 M |
$4.08 M |
$10.69 M |
$7.69 M |
$2.14 M |
$21.00 M |
-$28.03 M |
$3,000.00 |
-$1.30 M |
-$898,703.00 |
| Net Income |
$35.64 M |
-$8.63 M |
$11.99 M |
$14.31 M |
$31.90 M |
$51.94 M |
$81.45 M |
$2.57 M |
-$17.98 M |
-$6.05 M |
| Net Income Ratio |
0.11 |
-0.05 |
0.06 |
0.07 |
0.15 |
0.22 |
0.43 |
0.04 |
-0.94 |
-0.44 |
| EPS |
2.76 |
-0.66 |
0.89 |
1.04 |
2.16 |
3.44 |
5.24 |
0.17 |
-1.81 |
-0.57 |
| EPS Diluted |
2.73 |
-0.66 |
0.87 |
1.01 |
2.09 |
3.27 |
4.96 |
0.16 |
-1.81 |
-0.57 |
| Weighted Average Shares
Out |
$12.93 M
|
$13.05 M
|
$13.48 M
|
$13.75 M
|
$14.77 M
|
$15.10 M
|
$15.53 M
|
$15.25 M
|
$9.96 M
|
$10.57 M
|
| Weighted Average Shares
Out Diluted |
$13.07 M
|
$13.05 M
|
$13.77 M
|
$14.14 M
|
$15.28 M
|
$15.91 M
|
$16.43 M
|
$16.25 M
|
$9.96 M
|
$10.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
